Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Now dermatologists are increasingly prescribing the drug Rogaine, known generically as minoxidil, in low-dose pills to help ...

Discover how Meta's India, WhatsApp, and AI businesses are poised to drive growth and boost cash flows, shaping the company's ...

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical trade organisation that calls the campaign "nothing short ...

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Aamir Khan and Ranbir Kapoor engage in playful banter in Dream 11's latest ad. The fun peaks when Ranbir, caught in a ...

Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot ...

Hims & Hers Health Inc. (NYSE:HIMS) Hims & Hers rallied by 5.72 percent on Friday to finish at $34.75 apiece as investors loaded up on its shares despite the lack of catalysts to boost investing ...

Introduction: What Even Is Hims & Hers Health? In the pop culture of the investing community, Hims & Hers Health, Inc. (NYSE:HIMS) (Hims for short) has been described in all manner of ways ...